HR5355

This bill directs the Secretary of Health and Human Services to carry out activities to promote screenings for liver diseases in newborns. This is not merely a recommendation; it mandates HHS to actively promote these screenings, which translates into a direct increase in demand for diagnostic tests. The bill specifically mentions "routine direct-bilirubin measurement in the newborn heel-stick panel" as a clinically validated early-warning tool, indicating a clear focus on established screening methods and potential for new ones. This creates a new, federally supported market for pediatric liver disease diagnostics. The money trail for this initiative will primarily flow through increased procurement and reimbursement for diagnostic tests and related medical services. While the bill does not specify an appropriation amount, the mandate for HHS to "carry out activities to promote screenings" implies federal funding will be allocated to support these efforts, either through existing public health budgets or future appropriations. Diagnostic test manufacturers and clinical laboratories are directly positioned to capture this increased demand. Companies providing the necessary reagents, equipment, and testing services will see an uptick in business. Additionally, the emphasis on improved education for pediatric primary care providers will lead to increased referrals, benefiting pediatric liver specialists and related medical facilities. Historically, similar mandates for newborn screenings have led to sustained growth in the diagnostic sector. For example, the expansion of newborn screening panels for various metabolic and genetic disorders over the past two decades has consistently driven demand for specialized diagnostic tests. While specific market data for individual screening mandates is often integrated into broader diagnostic market trends, the overall market for newborn screening tests has grown steadily. For instance, the market for newborn screening is projected to grow at a CAGR of over 8% in the coming years, driven by expanded mandates and technological advancements. This bill aligns with that historical trend, ensuring continued growth in this niche. Specific companies positioned to benefit include those manufacturing diagnostic equipment and reagents, as well as large clinical laboratory service providers. Thermo Fisher Scientific ($TMO) is a major supplier of laboratory equipment, reagents, and diagnostic kits. Quest Diagnostics ($DGX) and LabCorp ($LH) are leading clinical laboratory service providers that perform a high volume of newborn screenings. Companies involved in genetic sequencing and advanced diagnostics, such as Illumina ($ILMN) and Qiagen ($QGEN), could also see increased demand for confirmatory or more advanced testing. Hologic ($HOLX), with its diagnostics portfolio, also stands to gain from increased screening volumes. Conversely, no companies are negatively impacted by this bill; it creates new market opportunities without restricting existing ones. The next step for this bill is committee review, specifically by the Committee on Energy and Commerce, as indicated in the bill text. Given the bipartisan sponsorship (Mr. Costa and Ms. Van Duyne) and the compelling findings regarding pediatric health, the bill has a strong chance of advancing. If it passes committee, it will proceed to a floor vote in the House, then to the Senate. The date of introduction, September 15, 2025, indicates this is a current legislative effort. The implementation timeline for HHS activities would commence upon enactment, likely within 6-12 months of becoming law.